André Schrattenholz

发表

Systems biology approaches and tools for analysis of interactomes and multi-target drugs.

André Schrattenholz, Karlfried Groebe, Vukic Soskic, 2010, Methods in molecular biology.

Proteomics: how to control highly dynamic patterns of millions of molecules and interpret changes correctly?

André Schrattenholz, A. Schrattenholz, 2004, Drug discovery today. Technologies.

Differential proteomic profiling of mitochondria from Podospora anserina, rat and human reveals distinct patterns of age-related oxidative changes

Heinz D. Osiewacz, André Schrattenholz, Karlfried Groebe, 2007, Experimental Gerontology.

Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing.

Tanja Waldmann, Karl-Heinz Krause, Marcel Leist, 2010, ALTEX.

The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions

Jeppe Falsig, Marcel Leist, André Schrattenholz, 2006, Journal of Neuroimmunology.

A connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis.

André Schrattenholz, Karlfried Groebe, G. Schwall, 2008, Journal of proteome research.

NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.

André Schrattenholz, A. Schrattenholz, Vukic Soskic, 2006, Current topics in medicinal chemistry.

Unexpected common mechanistic pathways for embryotoxicity of warfarin and lovastatin.

Katrin Hayess, Annelieke K Peters, Margino Steemans, 2010, Reproductive toxicology.

What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation of protein surrogate biomarkers

André Schrattenholz, Karlfried Groebe, K. Groebe, 2007, Electrophoresis.

What does systems biology mean for drug development?

André Schrattenholz, A. Schrattenholz, Vukić Soskić, 2008, Current medicinal chemistry.

How Human Embryonic Stem Cell Research Can Impact In‐Vitro Drug Screening Technologies of the Future

André Schrattenholz, A. Schrattenholz, Martina Klemm, 2006 .

Expression and prognostic relevance of annexin A3 in prostate cancer.

Martin Schostak, Helmut Klocker, Hartwig Huland, 2008, European urology.

Comparison of different separation technologies for proteome analyses: isoform resolution as a prerequisite for the definition of protein biomarkers on the level of posttranslational modifications.

André Schrattenholz, G. Schwall, A. Schrattenholz, 2006, Journal of chromatography. A.

Neurotoxicity of active compounds--establishment of hESC-lines and proteomics technologies for human embryo- and neurotoxicity screening and biomarker identification.

André Schrattenholz, A. Schrattenholz, Martina Klemm, 2004, ALTEX.

Neuronal cell culture from human embryonic stem cells as in vitro model for neuroprotection.

André Schrattenholz, A. Schrattenholz, Martina Klemm, 2007, ALTEX.

Synchronization of posttranslational modifications during aging

André Schrattenholz, Karlfried Groebe, K. Groebe, 2010, Annals of the New York Academy of Sciences.